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Abstract
Purpose—Despite the overlap between the clinical symptoms/sequelae of polycystic ovarian 
syndrome (PCOS) and many known reproductive risk factors for breast cancer, the relationship 
between PCOS and breast cancer remains unclear, possibly because of the complex heterogeneity 
and challenges in diagnosing PCOS over time. We hypothesized that PCOS, specific PCOS-related 
symptoms/sequelae, or clusters of PCOS-related symptoms/sequelae, may be differentially 
associated with pre- vs. postmenopausal breast cancer risk.
Materials and Methods—Cases were 1,508 women newly diagnosed with a first primary in 
situ or invasive breast, and the 1,556 population-based controls were frequency-matched by age.
Results—History of physician-diagnosed PCOS was reported by 2.2% (n=67), among whom 
oral contraceptive (OC) use, irregular menstruation, and infertility due to ovulatory dysfunction 
were common. Using unconditional logistic regression, adjusted odds ratios (95% confidence 
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intervals) for PCOS were increased for premenopausal [2.74 (1.13, 6.63)], but not post-
menopausal breast cancer [0.87 (0.44, 1.71)]. We used cluster analysis to investigate whether risk 
among all women varied by PCOS-related symptoms/sequelae, such as reproductive irregularities, 
OC use, and components of insulin resistance. In the cluster analysis, odds ratios were elevated 
among premenopausal women who had a history of OC use and no ovulatory dysfunction [1.39 
(1.03, 1.88)], compared to those with fewer number of PCOS-related symptoms/sequelae.
Conclusion—PCOS, and associated PCOS-related symptoms/sequelae including OC use, may 
play a role in the development of premenopausal breast cancer. Our findings require confirmation 
in studies with a larger number of premenopausal women with systematically applied diagnostic 
criteria for PCOS.
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Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrine condition in women of 
reproductive age with an estimated prevalence 2–18% [1,2]. PCOS is a complex, 
heterogeneous disorder of uncertain etiology characterized by hyperandrogenism, menstrual 
disturbances, and polycystic ovaries. The clinical manifestation of PCOS includes menstrual 
dysfunction, sub/infertility, hirsutism, acne, obesity, insulin insensitivity, and the metabolic 
syndrome [2]. Hyperinsulinemia and, resulting hyperandrogenemia have been investigated 
as possible causal factors for PCOS [3,4]. Elevated insulin levels contribute to the increased 
ovarian androgen production and decreased follicular maturation [4]. Because 
hyperinsulinemia also underpins the pathogenesis of the metabolic syndrome [5], PCOS has 
been considered the ‘ovarian’ manifestation of the metabolic syndrome [6].
The possible association between PCOS and breast cancer has been investigated because of 
the large overlap between the clinical manifestations of PCOS and risk factors for breast 
cancer [7–12]. Late age at menarche, and late age at first birth or nulliparity are typical 
clinical manifestations of PCOS [2,13], and are established risk factors for breast cancer 
[14–16]. The inverse relationship between physical activity and breast cancer risk is fairly 
consistent [17]. At the same time, a few studies have reported a possible inverse association 
between physical activity and PCOS [18, 19], but the association is not well established. 
Also, increased levels of androgen and insulin have been reported to be positively associated 
with the risk of breast cancer [20]. In addition, oral contraceptive (OC) use is one of the 
clinical sequelae of PCOS because OCs are the most widely applied treatment modality for 
PCOS to regulate menstrual cycles and decrease levels of free testosterone and hirsutism 
scores [21]; yet, OC use also has been consistently, albeit modestly, associated with elevated 
premenopausal breast cancer risk [22]. However, prior studies assessing the possible 
association between PCOS and breast cancer report conflicting results, including increased 
risk [23], decreased risk [7] and null results [9, 12, 24]. Inconsistent results may be due to 
the low prevalence of PCOS, thus making it difficult to conduct adequately powered PCOS-
related investigations. Further, the unclear etiology of PCOS along with changes in the 
diagnostic criteria of PCOS over time and the intra-individual variability of PCOS 
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symptoms, contribute to the challenges in the conceptualization of the study design as well 
as the statistical analysis when examining the potential PCOS-breast cancer association. 
However, understanding how the hormonal conditions of PCOS are related to breast cancer 
development is significant because it may clarify the underlying hormonal etiology of breast 
cancer, and perhaps PCOS itself.
Our study examines the association between PCOS and breast cancer risk using data from a 
population-based case-control study. Given the different risk factor profiles [25,26], 
pathologic, biologic and prognostic features of premenopausal compared to postmenopausal 
breast cancer [27], we also investigated if PCOS is differentially associated with pre- vs. 
postmenopausal breast cancer risk. Given the under-diagnosis and the changes in the 
diagnosis criteria overtime, we, for the first time, used a novel approach of cluster analysis to 
investigate the association between PCOS-related clinical symptoms/sequelae among all 
women (regardless of their PCOS diagnosis) and breast cancer risk.
Methods
The study reported here utilizes resources from the Long Island Breast Cancer Study Project 
(LIBCSP), a population-based study conducted among adult English-speaking female 
residents of Nassau and Suffolk counties, Long Island, NY. Details of the case-control study 
methods have been described elsewhere [28]. Institutional Review Board approval was 
obtained from all participating institutions.
Study Population
Eligible LIBCSP cases were women of all ages and races who were newly diagnosed with a 
first primary in situ or invasive breast cancer between August 1, 1996, and July 31, 1997. 
Cases were identified through daily or weekly contact with the 28 hospitals on Long Island 
and 3 large tertiary care hospitals in New York City.
Eligible controls were women without a personal history of breast cancer who were 
frequency matched to the expected age distribution of cases by 5-year age group. Controls 
were identified from among female residents of the same two Long Island counties as the 
cases using random digit dialing for women under the age of 65 years and Health Care 
Finance Administration rosters for women aged ≥65 years.
Response rates among eligible cases and controls were 82.1% (N= 1508) and 62.8% (N= 
1556), respectively. Participants ranged from 20–98 years of age, one-third were 
premenopausal, and 93% were white, 5% were black, and 2% were other. The racial 
distribution did not vary by case-control status, and reflects the racial distribution of the 
underlying population of Nassau and Suffolk counties at the time of data collection [28]. 
The distribution of other demographic and breast cancer risk factors among the study 
participants have been reported previously [28].
Brest cancer incidence in the LIBCSP population has been positively associated with: early 
age at menarche, late age at first birth and little or no breastfeeding [29]; use of oral 
contraceptives and hormone replacement [30]; use of alcohol [31], and little or no use of 
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aspirin and other NSAIDs [32]; and, among postmenopausal women only, obesity [33] and 
physical inactivity [17].
History of PCOS and PCOS-related Clinical Symptoms/Sequelae
Participants completed a 100-minute structured questionnaire conducted by a trained 
interviewer in the respondent’s home shortly after diagnosis (or date of identification for 
controls). As part of the case-control questionnaire, interviewers asked participants if a 
health professional had ever told them that they had polycystic ovarian syndrome (‘yes’, ‘no’ 
or ‘don’t know’). Interviewers also asked participants: at what age their menstrual periods 
became regular or if it never became regular; and if their periods became regular naturally, 
because of birth pills, or in some other way. Other PCOS-related symptoms/sequelae such as 
acne, obesity (weight and height), OC use, history of infertility, age at menarche and age at 
first birth were also assessed at the interview, and covariates were defined based on the 
Rotterdam criteria and previous studies regarding clinical features of PCOS [34, 35]. The 
interviewers also inquired if the participants had physician-diagnosed diseases that are 
associated with metabolic syndrome such as hypertension, diabetes mellitus and 
hypercholesterolemia.
Other Covariate Assessment
The case-control interviewers queried women on demographic characteristics, cigarette 
smoking and physical activity levels. Details of the methods used to assess smoking [36], 
and physical activity [17] have been described previously. Among eligible cases, clinical 
data on the characteristics of their breast cancer diagnosis, including hormone receptor 
status, were obtained from medical records.
Statistical Analysis
We first examined distributions of demographic and breast cancer risk factors among women 
with and without PCOS, among all women. Also, because risk factor profiles may vary by 
pre-and postmenopausal breast cancer [29][30], we examined the prevalence of symptoms/
sequelae by menopausal status.
Unconditional logistic regression was used to estimate odds ratios (ORs) and 95% 
confidence intervals (CIs) for associations of PCOS and breast cancer risk [37]. All 
statistical models were implemented in SAS, version 9.2 (SAS Institute Inc., Cary, NC). 
History of PCOS (yes/no) was evaluated as dichotomous variable; women who were not 
sure about their PCOS diagnosis were considered not to have PCOS history.
We identified potential confounders through the known epidemiology of breast cancer 
[15,16], PCOS and analysis of causal diagrams (Fig. 1) [38]. Careful consideration of our 
causal diagram identified the following as mediators of the association between the study 
exposure (PCOS) and the study outcome (breast cancer), and were thus excluded from all 
models: history of infertility; parity/gravidity; body mass index (BMI = weight in kilograms/
height in meters squared); physician-diagnosed diabetes mellitus/hypertension/
hypercholesterolemia, irregular menstruation; and ever OC use [39]. Covariates considered 
as potentials confounders included average lifetime physical activity (<0.1 hrs/week, 0.1–
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3.59 hrs/week, 3.6–10.49 hrs/week, and ≥10.5 hrs/week) and cigarette smoking history 
(never/ever). Covariates resulting in >10% change in the regression coefficient when added 
to the model, compared to a model without the covariate, were included as confounders in 
our final analysis [40]; physical activity, but not smoking, met this criterion. Thus, final 
multivariable models were adjusted for physical activity, and the frequency matching factor, 
5-year age group.
Menopausal status (premenopausal/postmenopausal) at diagnosis (cases) or at interview 
(controls) was investigated as a potential effect measure modifier based on our a priori study 
aims. Departure from the multiplicative null was assessed using the likelihood ratio test [37].
The age range of the LIBCSP study subjects was wide, and thus the criteria used to define a 
diagnosis of PCOS is likely to have varied over time. Also, many of the symptoms/sequelae 
of PCOS are likely to be independently associated with breast cancer, and are likely 
mediators for any association observed between PCOS and breast cancer. Thus, using 
adjusted logistic regression models, the associations between breast cancer risk and the 
symptoms/sequelae of PCOS (including acne, increased BMI, OCs use, history of infertility, 
age at menarche, age at first birth, and history of diabetes mellitus, hypertension, and 
hypercholesterolemia) were examined among all women, regardless of their PCOS history 
[41]. Many of the effect estimates for the individual associations between breast cancer risk 
and each of these PCOS symptoms/sequelae in the LIBCSP study population have already 
been reported [17, 29, 30, 42], but are reported here to ease interpretation of our cluster 
analysis (see below).
Using k-means cluster analysis [43], all participants (regardless of their PCOS diagnosis) 
were grouped according to PCOS symptoms/sequelae. PCOS-related symptoms/sequelae 
considered in the cluster analysis included: ovulatory dysfunction (fail to initiate regular 
cycles naturally or history of infertility due to ovulatory dysfunction); metabolic syndrome-
related sequelae (history of hypertension, diabetes mellitus, or hypercholesterolemia); late 
age at menarche; late age at first birth; current or past OC use; and overweight/obesity 
(current BMI > 25kg/m2). Using model fit and clinical relevance, participants were grouped 
into six clusters. We then used logistic regression to examine the association between each 
cluster group (entered as a dichotomous categorical variable, using the cluster with the 
fewest PCOS-related symptoms as the referent) and breast cancer risk. We also considered 
these associations stratified by menopausal status.
Results
PCOS characteristics
Among the 3,046 LIBCSP study participants (1,508 cases and 1,556 controls), 67 (2.2%) 
reported a PCOS diagnosis from a medical professional and 2,951 (96.3%) reported no 
PCOS history. The 46 women (1.5%) who were not sure about their PCOS diagnosis were 
considered not to have PCOS history. As shown in Table 1, participants with PCOS history 
were significantly younger than participants without PCOS history (p=0.008).
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Participants with PCOS were more likely to have ever used OCs (p=0.05) and to have a 
history of infertility due to ovulatory dysfunction (p=0.001); and to not to have regular 
menstrual cycles naturally (p=0.002). In contrast, distributions for parity, age at menarche, 
age at first birth, BMI, hypertension, diabetes mellitus, hypercholesterolemia, and active 
smoking were not substantially different from women without PCOS. Among breast cancer 
cases, the proportion diagnosed with in situ vs. invasive disease was similar for women with 
and without PCOS. As shown in Fig. 2, metabolic syndrome-related sequelae were the most 
frequent PCOS-related symptoms/sequelae among all and postmenopausal participants, 
whereas history of using OCs was the most frequent symptoms/sequelae among 
premenopausal subjects.
PCOS and breast cancer risk
Among all women, the age-adjusted effect estimate for the association between PCOS and 
breast cancer incidence was elevated by 43%, but the confidence intervals were wide (age-
adjusted OR= 1.43; 95% CI= 0.80, 2.20); the estimate was similar in multivariate models 
(multivariate adjusted OR= 1.37; 95% CI= 0.81–2.29) (Table 2). However, risk varied 
significantly by menopausal status (p-value for multiplicative interaction=0.05). In 
premenopausal women, breast cancer incidence was increased nearly 3-fold among women 
with PCOS as compared to women without PCOS (multivariate-adjusted OR= 2.74; 95% 
CI= 1.13–6.63). In contrast, for postmenopausal women, breast cancer incidence was 
decreased by 33% among women with a history of PCOS (multivariate-adjusted OR= 0.67; 
95% CI= 0.33–1.35).
Individual PCOS-related clinical symptoms/sequelae and breast cancer risk
As shown in Table 3, neither pre- nor postmenopausal breast cancer incidence among all 
women (regardless of PCOS history) was associated with the history of the initiation of 
regular menstruation and infertility due to ovulatory dysfunction. As previously reported 
[17, 29, 30, 42, 44] and as shown in Table 3, breast cancer risk was significantly elevated 
among all women (regardless of PCOS history) with characteristics that are often associated 
with PCOS. Women with breast cancer were more likely to be nulliparous, and the 
association was strongest among postmenopausal women. Among women who had their 
first birth at later age (≥28 years), the risk of breast cancer was elevated, and ever use of OCs 
was associated with increased odds of developing premenopausal breast cancer. Obesity and 
a history of physician-diagnosed diabetes mellitus were associated with increased 
postmenopausal breast cancer risk, and decreased premenopausal breast cancer risk.
Clusters of PCOS-related clinical symptoms/sequelae and breast cancer risk
We used cluster analysis to investigate if constellations of various PCOS-related symptoms/
sequelae are related to breast cancer risk, which resulted in all women (regardless of their 
PCOS history) being grouped into six clusters according to PCOS-related symptoms/
sequelae (Table 4A). All women in cluster 1 and 2 had used OCs. Women in cluster 1 tended 
to have higher prevalence of ovulatory dysfunction while those in cluster 3 did not. Cluster 2 
was characterized as high prevalence of OC use and low ovulatory dysfunction. Women in 
cluster 6 had the highest prevalence of metabolic syndrome-related symptoms/sequelae and 
were more likely to be obese compared to subjects in other clusters. Women in cluster 4 had 
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the lowest prevalence of PCOS-related symptoms/sequelae overall; thus, we selected cluster 
4 as the referent category for our cluster analyses.
Breast cancer risk among all women showed little or no variation across clusters of PCOS-
related symptoms/sequelae, as compared to cluster 4 (Table 4B). However, premenopausal 
breast cancer incidence was increased by 39% among women in cluster 2 (age-adjusted 
OR=1.39; 95% CI =1.03, 1.88), and the confidence intervals excluded the null value. 
Premenopausal breast cancer incidence was also increased among women in cluster 1 
compared to those in cluster 4, however the confidence intervals included the null value 
(age-adjusted OR=1.35; 95% CI =0.84, 2.17). For postmenopausal breast cancer, the odds 
ratios tended to decrease for all clusters, however, confidence intervals included the null 
value.
Discussion
In this population-based study, we observed a pronounced, nearly 3-fold increase in risk for 
a history of physician-diagnosed PCOS in association with premenopausal, but not 
postmenopausal, breast cancer. History of irregular menses, infertility, and OC use were 
more commonly reported by women with PCOS, than those without PCOS. However, in our 
cluster analysis that considered PCOS-related symptoms/sequelae among all women, OC 
use was the only symptom/sequelae for which the risk of premenopausal breast cancer was 
elevated.
Although our results are provocative, they must be interpreted with care. Despite the notable 
overlap of risk factors between breast cancer and PCOS-related symptoms/sequelae, 
previous research has reported increased [23], no altered risk [9,12,24], or decreased risk of 
breast cancer [7], in relation to a history of PCOS. There are few studies showing differences 
by menopausal status [7,23]. In a population based case-control study evaluating 4,730 
women with breast cancer and 4,688 control women aged 20–54 years, Gammon and 
colleagues reported a 50% decrease in breast cancer risk among women with PCO, which 
did not vary by menopausal status [7]. In contrast, our finding here showed significantly 
increased risk of premenopausal breast cancer with PCOS which is consistent with Cowan et 
al.'s report showing an increased premenopausal breast cancer risk in women with 
progesterone deficiency [23]. The inconsistency of the results between previous reports and 
our own may stem from differences in the analytic approach and in the distribution of PCOS 
symptoms/sequelae across study populations. Previous researchers included adjustments for 
many variables that are most likely mediators of the PCOS-breast cancer association [7–
10,12], and thus should not be included in the statistical models [46]; as shown in Fig. 1, 
these mediators include history of infertility, parity, BMI, or history of OCs use. Adjusting 
for mediators is likely to attenuate and reduce the precision of the effect estimate for the 
PCOS-breast cancer association [45].
The diagnosis of PCOS is made based on its symptoms and the various symptoms may be 
independently associated with breast cancer risk. Also, because of the wide spectrum of 
clinical features and the interconnection among those features of PCOS, women with PCOS 
tend to present with multiple and heterogeneous clinical symptoms or sequelae. Thus, when 
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exploring the association between PCOS and breast cancer, it may be informative to 
consider the impact of the constellation of various PCOS symptoms and sequelae, 
individually as well as grouped. Interestingly, in our cluster analysis that included all 
women, breast cancer risk increase was highest among premenopausal women who had used 
OCs (cluster 1 and 2). However, there was no notable risk change in women with metabolic 
syndrome-related symptoms and sequelae (cluster 5 and 6) or in women who had ovulatory 
dysfunction without OC use (cluster 3). Although our approach cannot definitively 
differentiate the impact of OC use on breast cancer risk between women with and without 
PCOS, it is possible that the increased premenopausal breast cancer risk in women with 
PCOS is not related to PCOS itself or PCOS-related symptoms/sequelae, but is possibly 
associated, at least in part, with the high prevalence of OCs use in this population.
A possible reason for our observed increase for the PCOS-breast cancer association among 
premenopausal women only is that PCOS is a disease of premenopausal women given the 
clinical features of PCOS are not easily discerned among postmenopausal women. So, it 
may be possible that clinical features and the aberrant hormonal profile of PCOS impact 
only premenopausal breast cancer, which attenuates with time once exposure to PCOS 
dissipates. Our cluster analysis among women with and without PCOS, revealed that from 
among all PCOS-related symptoms/sequelae, the clusters which included women who had 
ever used OCs were most strongly associated with breast cancer. Given that OCs are used 
only by premenopausal women, their use by women with PCOS requires closer scientific 
and clinical examination. To elucidate the exact relationship between OC use and 
premenopausal breast cancer development in women with PCOS, a mediation analysis 
would be appropriate, which is not possible in this study due to the case-control design [46].
Our study has several significant strengths. Our novel approach of clustering women 
according to their history of these factors mitigates the impact of low prevalence and under-
diagnosis of PCOS and may be clinically useful and practical. In addition, our cluster 
approach can be helpful in elucidating the possible association which results from specific 
clinical symptoms/sequelae of PCOS versus the clinical manifestation of PCOS. However, 
our clusters were derived using our primarily white population-based study sample and thus 
may not be applicable to other more racially diverse populations. Also, ours is the first study 
to exclude all mediators of the PCOS-breast cancer association in the model. Finally, by 
suggesting the possible role of OCs in women with PCOS, our results help to inform future 
research focused on the potential breast cancer risk versus any potential benefits associated 
with OC use among women with PCOS.
There are several limitations in this study. First, despite the large overall sample size, the 
prevalence of PCOS was low in our study population, and thus we were unable to conduct 
more detailed statistical analyses, including consideration of: (1) a potential interaction 
between OC use and PCOS on breast cancer risk; (2) potential heterogeneity of the 
association with breast cancer subtypes, including subtypes defined by hormone receptor 
status; and (3) potential differential recall of a history of PCOS due to age at recruitment. 
Second, the study is based on self-reported history of PCOS, which is subject to errors in 
recall. However, despite the small number of women who reported a history of PCOS, the 
overall prevalence of PCOS and the clinical sequelae of PCOS among the LIBCSP study 
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population were consistent with previous reports [2], particularly those based on studies 
conducted among a population-based sample [1]. Third, our study population is fairly 
racially homogenous, with more than 90% of participants who self-reported their race as 
white. Although, we were unable to investigate the role of race on the association between 
PCOS and breast cancer, the population homogeneity increases internal validity of our study. 
Fourth, we were unable to consider hirsutism, which is a significant clinical feature of 
PCOS, as one of PCOS-related symptom/sequelae in our cluster analysis, because 
assessment of hirsutism was not included in the LIBCSP questionnaire. Finally, the response 
rate between cases and controls differed. However, the LIBCSP control response rate is 
comparable to that found in other population-based control studies [28].
In summary, in this population-based study, we found a strong positive association between 
PCOS and premenopausal breast cancer. We also observed modest increased risks among 
premenopausal women with select clusters of PCOS-related symptoms and sequelae, which 
included those who reported OC use. Future investigations, with larger numbers of 
premenopausal women and systematically applied criteria for defining PCOS, are required 
to confirm our findings.
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Figure 1. 
A simplified directed acyclic graph for the association between PCOS and breast cancer.
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Figure 2. 
Frequencies (percent) of PCOS-related clinical symptoms/sequelae among all, 
premenopausal and postmenopausal women, LIBCSP, 1996–1997.
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Table 1
The distribution of demographic factors, reproductive and medical history, by PCOS history among all 
subjects (cases (n=1508) and controls (n = 1556)), LIBCSP 1996–1997.
Factor PCOS (n=67) No PCOS (n=2,997) Total (n=3,064)
Age 53.8±12.2 58.0±12.8 57.8±12.8
BMI (kg/m2) 27.4±6.2 26.5±5.7 26.5±5.7
BMI at age 20 (kg/m2) 21.4±3.9 20.9±3.1 20.9±3.2
Parity (%)
 0 10 (14.9) 359 (12.0) 369 (12.0)
 1 7 (10.5) 307 (10.5) 314 (10.5)
 ≥2 50 (74.6) 2,331 (77.5) 2,381 (77.4)
Race (%)
 White 63 (94.0) 2,777 (92.8) 2,840 (92.8)
 Black and other <5 217 (7.2) 221 (7.2)
Age at menarche (years) 12.4±7.5 12.6±1.6 12.6±1.6
Age at first birth (years) 25.1±3.8 25.3±4.6 25.3±4.6
No. of postmenopausal women (%) 35 (55.6) 1,961 (67.4) 1,996 (65.1)
Physical activity (hours/week) 6.4±10.2 7.3±10.0 7.3±10.0
Ever use of oral contraceptives (%) 37 (55.2) 1335 (44.6) 1,372 (44.8)
Family history of breast cancer (%) 12 (18.5) 480 (16.5) 492 (16.6)
Periods never became regular naturally (%) 16 (24.2) 299 (10.3) 315 (10.6)
History of infertility due to ovulatory dysfunction (%) 6 (12.0) 44 (1.7) 50 (1.9)
Metabolic syndrome-related sequelae (%)
 Hypertension 21 (33.3) 999 (34.4) 1,020 (34.4)
 Diabetes mellitus <5 236 (8.1) 239 (8.0)
 Hypercholesterolemia 22 (34.9) 888 (30.5) 910 (30.6)
History of active smoking (%) 37 (57.8) 1,616 (55.3) 1,653 (55.4)
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Table 2
Odds ratios [and 95% confidence intervals] for the association between a history of PCOS and breast cancer 
incidence, by menopausal status, LIBCSP, 1996–1997.
History of PCOS Cases (N=1,508) Controls (N=1,556) Age-adjusted OR (95% CI) Multivariable-adjusted ORa (95% 
CI)
All women
 No PCOS 1,503 1,448 Ref Ref
 PCOS 38 29 1.43 (0.88, 2.34) 1.37 (0.81, 2.29)
Premenopausal women
 No PCOS 448 489 Ref Ref
 PCOS 19 9 2.31 (1.03, 5.17) 2.74 (1.13, 6.63)
Postmenopausal women
 No PCOS 973 954 Ref Ref
 PCOS 16 19 0.87 (0.44, 1.71) 0.67 (0.33, 1.35)
aAdjusted for age and physical activity (hrs/week)
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